SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali
Copyright © 2024. Published by Elsevier Ltd..
OBJECTIVES: The InVITE study, starting in August 2021, was designed to examine the immunogenicity of different vaccine regimens in several countries including the Democratic Republic of Congo, Guinea, Liberia, and Mali. Prevaccination baseline samples were used to obtain estimates of previous SARS-CoV-2 infection in the study population.
METHODS: Adult participants were enrolled upon receipt of their initial COVID-19 vaccine from August 2021 to June 2022. Demographic and comorbidity data were collected at the time of baseline sample collection. SARS-CoV-2 serum anti-Spike and anti-Nucleocapsid antibody levels were measured.
RESULTS: Samples tested included 1016, 375, 663, and 776, from DRC, Guinea, Liberia, and Mali, respectively. Only 0.8% of participants reported a prior positive SARS-CoV-2 test, while 83% and 68% had anti-Spike and anti-Nucleocapsid antibodies, respectively.
CONCLUSIONS: Overall SARS-CoV-2 seroprevalence was 86% over the accrual period, suggesting a high prevalence of SARS-CoV-2 infection. Low rates of prior positive test results may be explained by asymptomatic infections, limited access to SARS-CoV-2 test kits and health care, and inadequate surveillance. These seroprevalence rates are from a convenience sample and may not be representative of the population in general, underscoring the need for timely, well-conducted surveillance as part of global pandemic preparedness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:142 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 142(2024) vom: 12. Apr., Seite 106985 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laverdure, Sylvain [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2024.106985 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369075285 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369075285 | ||
| 003 | DE-627 | ||
| 005 | 20240416232614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2024.106985 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM369075285 | ||
| 035 | |a (NLM)38417612 | ||
| 035 | |a (PII)S1201-9712(24)00056-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laverdure, Sylvain |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVES: The InVITE study, starting in August 2021, was designed to examine the immunogenicity of different vaccine regimens in several countries including the Democratic Republic of Congo, Guinea, Liberia, and Mali. Prevaccination baseline samples were used to obtain estimates of previous SARS-CoV-2 infection in the study population | ||
| 520 | |a METHODS: Adult participants were enrolled upon receipt of their initial COVID-19 vaccine from August 2021 to June 2022. Demographic and comorbidity data were collected at the time of baseline sample collection. SARS-CoV-2 serum anti-Spike and anti-Nucleocapsid antibody levels were measured | ||
| 520 | |a RESULTS: Samples tested included 1016, 375, 663, and 776, from DRC, Guinea, Liberia, and Mali, respectively. Only 0.8% of participants reported a prior positive SARS-CoV-2 test, while 83% and 68% had anti-Spike and anti-Nucleocapsid antibodies, respectively | ||
| 520 | |a CONCLUSIONS: Overall SARS-CoV-2 seroprevalence was 86% over the accrual period, suggesting a high prevalence of SARS-CoV-2 infection. Low rates of prior positive test results may be explained by asymptomatic infections, limited access to SARS-CoV-2 test kits and health care, and inadequate surveillance. These seroprevalence rates are from a convenience sample and may not be representative of the population in general, underscoring the need for timely, well-conducted surveillance as part of global pandemic preparedness | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a InVITE | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Seroprevalence | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a West Africa | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Kazadi, Donatien |e verfasserin |4 aut | |
| 700 | 1 | |a Kone, Kadidia |e verfasserin |4 aut | |
| 700 | 1 | |a Callier, Viviane |e verfasserin |4 aut | |
| 700 | 1 | |a Dabitao, Djeneba |e verfasserin |4 aut | |
| 700 | 1 | |a Dennis, Dehkontee |e verfasserin |4 aut | |
| 700 | 1 | |a Haidara, Mory Cherif |e verfasserin |4 aut | |
| 700 | 1 | |a Hunsberger, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Mbaya, Olivier Tshiani |e verfasserin |4 aut | |
| 700 | 1 | |a Ridzon, Renee |e verfasserin |4 aut | |
| 700 | 1 | |a Sereti, Irini |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw-Saliba, Katy |e verfasserin |4 aut | |
| 700 | 0 | |a InVITE Study Team |e verfasserin |4 aut | |
| 700 | 1 | |a Akpa, Esther |e investigator |4 oth | |
| 700 | 1 | |a Bah, Fatoumata Binta |e investigator |4 oth | |
| 700 | 1 | |a Barash, Yi-Chi |e investigator |4 oth | |
| 700 | 1 | |a Beavogui, Abdoul Habib |e investigator |4 oth | |
| 700 | 1 | |a Biampata, Jean-Luc |e investigator |4 oth | |
| 700 | 1 | |a Bonnett, Tyler |e investigator |4 oth | |
| 700 | 1 | |a Brown, Shawn |e investigator |4 oth | |
| 700 | 1 | |a Burkey, Alissa |e investigator |4 oth | |
| 700 | 1 | |a Camara, Daouda |e investigator |4 oth | |
| 700 | 1 | |a Camara, Sekou |e investigator |4 oth | |
| 700 | 1 | |a Cline-Cole, Elfrida |e investigator |4 oth | |
| 700 | 1 | |a Coulibaly, Mamadou D |e investigator |4 oth | |
| 700 | 1 | |a Coulibaly, Nadie |e investigator |4 oth | |
| 700 | 1 | |a Dewar, Robin |e investigator |4 oth | |
| 700 | 1 | |a Diallo, Mountaga |e investigator |4 oth | |
| 700 | 1 | |a Diarra, Samba |e investigator |4 oth | |
| 700 | 1 | |a Doumbia, Seydou |e investigator |4 oth | |
| 700 | 1 | |a Eyler, Allison |e investigator |4 oth | |
| 700 | 1 | |a Fouth Tchos, Karine |e investigator |4 oth | |
| 700 | 1 | |a Francis, Alyson |e investigator |4 oth | |
| 700 | 1 | |a Grue, Louis |e investigator |4 oth | |
| 700 | 1 | |a Highbarger, Helene |e investigator |4 oth | |
| 700 | 1 | |a Highbarger, Jeroen |e investigator |4 oth | |
| 700 | 1 | |a Ibanda, Augustin Mbala |e investigator |4 oth | |
| 700 | 1 | |a Kallon, Kadé |e investigator |4 oth | |
| 700 | 1 | |a Kindombe, Esaie Luzolu |e investigator |4 oth | |
| 700 | 1 | |a Kingebeni, Placide Mbala |e investigator |4 oth | |
| 700 | 1 | |a Kolié, Cece Francis |e investigator |4 oth | |
| 700 | 1 | |a Lallemand, Perrine |e investigator |4 oth | |
| 700 | 1 | |a Lim, Caeul |e investigator |4 oth | |
| 700 | 1 | |a Lokilo, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Lumembe, Raphael |e investigator |4 oth | |
| 700 | 1 | |a McCormack, Ashley Louise |e investigator |4 oth | |
| 700 | 1 | |a McNay, Laura |e investigator |4 oth | |
| 700 | 1 | |a Mukendi, Gael |e investigator |4 oth | |
| 700 | 1 | |a Mukendi, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Muyembe, Jean Jacques |e investigator |4 oth | |
| 700 | 1 | |a Newell, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Njoh, Wissedi |e investigator |4 oth | |
| 700 | 1 | |a Pankwa, Isaac Balmayel |e investigator |4 oth | |
| 700 | 1 | |a Pukuta, Elisabeth |e investigator |4 oth | |
| 700 | 1 | |a Riziki, Yogolelo |e investigator |4 oth | |
| 700 | 1 | |a Rupert, Adam |e investigator |4 oth | |
| 700 | 1 | |a Samake, Seydou |e investigator |4 oth | |
| 700 | 1 | |a Sandrus, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Sangare, Adama |e investigator |4 oth | |
| 700 | 1 | |a Smolskis, Mary |e investigator |4 oth | |
| 700 | 1 | |a Souto Adeva, Gema |e investigator |4 oth | |
| 700 | 1 | |a Stevens, Randy |e investigator |4 oth | |
| 700 | 1 | |a Tangara, Cheick Oumar |e investigator |4 oth | |
| 700 | 1 | |a Tounkara, Moctar |e investigator |4 oth | |
| 700 | 1 | |a Trumbull-Kennedy, Meghan |e investigator |4 oth | |
| 700 | 1 | |a Tshomba, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Wague, Mamadou |e investigator |4 oth | |
| 700 | 1 | |a Weyers, Shera |e investigator |4 oth | |
| 700 | 1 | |a Worthington, Chris |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 142(2024) vom: 12. Apr., Seite 106985 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:2024 |g day:12 |g month:04 |g pages:106985 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2024.106985 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 2024 |b 12 |c 04 |h 106985 | ||